The added value of ordinal analysis in clinical trials: an example in traumatic brain injury

被引:125
作者
Roozenbeek, Bob [1 ,2 ]
Lingsma, Hester F. [2 ]
Perel, Pablo
Edwards, Phil [3 ]
Roberts, Ian [3 ]
Murray, Gordon D. [4 ]
Maas, Andrew I. R. [1 ]
Steyerberg, Ewout W. [2 ]
机构
[1] Univ Antwerp Hosp, Dept Neurosurg, B-2650 Edegem, Belgium
[2] Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands
[3] Univ London London Sch Hyg & Trop Med, Epidemiol & Populat Hlth Dept, London WC1E 7HT, England
[4] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland
来源
CRITICAL CARE | 2011年 / 15卷 / 03期
基金
美国国家卫生研究院; 英国医学研究理事会;
关键词
RANDOMIZED CONTROLLED-TRIALS; NEUROPROTECTIVE AGENTS; OUTCOME SCALES; ACUTE STROKE; HEAD-INJURY; EFFICACY; DESIGN;
D O I
10.1186/cc10240
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Introduction: In clinical trials, ordinal outcome measures are often dichotomized into two categories. In traumatic brain injury (TBI) the 5-point Glasgow outcome scale (GOS) is collapsed into unfavourable versus favourable outcome. Simulation studies have shown that exploiting the ordinal nature of the GOS increases chances of detecting treatment effects. The objective of this study is to quantify the benefits of ordinal analysis in the real-life situation of a large TBI trial. Methods: We used data from the CRASH trial that investigated the efficacy of corticosteroids in TBI patients (n = 9,554). We applied two techniques for ordinal analysis: proportional odds analysis and the sliding dichotomy approach, where the GOS is dichotomized at different cut-offs according to baseline prognostic risk. These approaches were compared to dichotomous analysis. The information density in each analysis was indicated by a Wald statistic. All analyses were adjusted for baseline characteristics. Results: Dichotomous analysis of the six-month GOS showed a non-significant treatment effect (OR = 1.09, 95% CI 0.98 to 1.21, P = 0.096). Ordinal analysis with proportional odds regression or sliding dichotomy showed highly statistically significant treatment effects (OR 1.15, 95% CI 1.06 to 1.25, P = 0.0007 and 1.19, 95% CI 1.08 to 1.30, P = 0.0002), with 2.05-fold and 2.56-fold higher information density compared to the dichotomous approach respectively. Conclusions: Analysis of the CRASH trial data confirmed that ordinal analysis of outcome substantially increases statistical power. We expect these results to hold for other fields of critical care medicine that use ordinal outcome measures and recommend that future trials adopt ordinal analyses. This will permit detection of smaller treatment effects.
引用
收藏
页数:7
相关论文
共 28 条
[1]   Delta inflation: A bias in the design of randomized controlled trials in critical care medicine [J].
Aberegg S.K. ;
Richards D.R. ;
O'Brien J.M. .
Critical Care, 14 (2)
[2]   Statistics notes - The cost of dichotomising continuous variables [J].
Altman, DG ;
Royston, P .
BRITISH MEDICAL JOURNAL, 2006, 332 (7549) :1080-1080
[3]   Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials [J].
Bath, Philip M. W. .
STROKE, 2007, 38 (06) :1911-1915
[4]   The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial [J].
den Hertog, Heleen M. ;
van der Worp, H. Bart ;
van Gemert, H. Maarten A. ;
Algra, Ate ;
Kappelle, L. Jaap ;
Van Gijn, Jan ;
Koudstaal, Peter J. ;
Dippel, Diederik W. J. .
LANCET NEUROLOGY, 2009, 8 (05) :434-440
[5]  
Edwards P, 2005, LANCET, V365, P1957
[6]   Adjustment for strong predictors of outcome in traumatic brain injury trials:: 25% reduction in sample size requirements in the IMPACT study [J].
Hernandez, Adrian V. ;
Steyerberg, Ewout W. ;
Butcher, Isabella ;
Mushkudiani, Nino ;
Taylor, Gillian S. ;
Murray, Gordon D. ;
Marmarou, Anthony ;
Choi, Sung C. ;
Lu, Juan ;
Habbema, J. Dik F. ;
Maas, Andrew I. R. .
JOURNAL OF NEUROTRAUMA, 2006, 23 (09) :1295-1303
[7]   NXY-059 for acute ischemic stroke [J].
Lees, KR ;
Zivin, JA ;
Ashwood, T ;
Davalos, A ;
Davis, SM ;
Diener, H ;
Grotta, J ;
Lyden, P ;
Shuaib, A ;
Hårdemark, H ;
Wasiewski, WW .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :588-600
[8]   Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial [J].
Lees, KR ;
Asplund, K ;
Carolei, A ;
Davis, SM ;
Diener, HC ;
Kaste, M ;
Orgogozo, JM ;
Whitehead, J .
LANCET, 2000, 355 (9219) :1949-1954
[9]   Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoretical considerations [J].
Maas, AIR ;
Steyerberg, EW ;
Murray, GD ;
Bullock, R ;
Baethmann, A ;
Marshall, LF ;
Teasdale, GM .
NEUROSURGERY, 1999, 44 (06) :1286-1298
[10]   Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial [J].
Maas, AIR ;
Murray, G ;
Henney, H ;
Kassem, N ;
Legrand, V ;
Mangelus, M ;
Muizelaar, JP ;
Stocchetti, N ;
Knoller, N .
LANCET NEUROLOGY, 2006, 5 (01) :38-45